JUL 3 0 2001 BY

CASE DO016 NP

## CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico

Type or print name

Signature

8/26/2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1635

RECEIVED

CARROLL ET AL.

APPLICATION NO: 09/813,329

AUG 0 2 2001

FILED: MARCH 20, 2001

**TECH CENTER 1600/2900** 

FOR: NOVEL DROSOPHILA TUMOR NECROSIS FACTOR CLASS

MOLECULE ("DMTNF") AND VARIANTS THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date:

Agent for Applicants Reg. No. 46,652

Stephen C. D'Amico